Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel [0.03%]
血管内皮生长因子多态性与每周使用多西他赛治疗转移性乳腺癌患者的临床结果的关系
A K Koutras,V Kotoula,C Papadimitriou et al.
A K Koutras et al.
The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a phase II trial. This study evaluated weekly docetaxel, as first-line treatment for metastatic breast ca...
Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies [0.03%]
基于观察性关联研究解读药物基因组标志物的临床效用
M J Sorich,M Coory
M J Sorich
It is increasingly recognized that the clinical utility of a pharmacogenomic marker is a fundamental characteristic influencing the likelihood of successful clinical translation. Although appropriately designed and executed randomized contr...
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans [0.03%]
华法林在非裔美国人中的种族特异性药物基因组学研究
W Hernandez,E R Gamazon,K Aquino-Michaels et al.
W Hernandez et al.
Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our nov...
Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia [0.03%]
南澳大利亚阿德莱德医院药剂师的药物基因组学实践的认识、障碍和驱动力调查研究
M M Dias,H M Ward,M J Sorich et al.
M M Dias et al.
There is little literature regarding the barriers to the uptake of pharmacogenomics (PG) in pharmacy practice, especially with respect to Australia. To date, pharmacists have seldom been engaged in discussions of these issues. This study ai...
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer [0.03%]
ABCB1、ABCC1和ALDH1A1胚系遗传变异体在SWOG三期临床试验S0221中参与乳腺癌的血液学及胃肠道毒性的风险评估研究
S Yao,L E Sucheston,H Zhao et al.
S Yao et al.
Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated ...
Clinical Trial
The pharmacogenomics journal. 2014 Jun;14(3):241-7. DOI:10.1038/tpj.2013.32 2014
The potential impact of pharmacogenetic testing on medication adherence [0.03%]
药物基因组检测对服药依从性潜在影响的研究
S B Haga,N M A LaPointe
S B Haga
Poor medication adherence is a well-known problem, particularly in patients with chronic conditions, and is associated with significant morbidity, mortality and health-care costs. Multi-faceted and personalized interventions have shown the ...
Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial [0.03%]
遗传检测结果影响患者他汀类药物依从性：Additional KIF6 Risk Offers Better Adherence to Statins(AKROBATS)试验结果
S L Charland,B C Agatep,V Herrera et al.
S L Charland et al.
Despite the clinical benefit of statin therapy and the numerous strategies used to improve adherence, no strategy has used direct communication of genetic test results to the patient as an adherence and persistence motivator. We investigate...
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain [0.03%]
西班牙和古巴的 Hispanic人群中的CYP2C9基因型和环境因素对消炎镇痛药双氯酚酸代谢影响的族裔差异性研究
A Llerena,M Alvarez,P Dorado et al.
A Llerena et al.
The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain and its relation to ethnicity, CYP2C9 genotypes and environmental factors. Diclofenac hydroxylation capacity (concentration ratios of diclofe...
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan [0.03%]
表皮生长因子受体抗体联合伊立替康治疗转移性结直肠癌患者时ampiregulin基因区的遗传多态性作为生物标志物的作用
A Sebio,D Páez,J Salazar et al.
A Sebio et al.
In the epidermal growth factor receptor (EGFR) pathway, polymorphisms in EGFR and its ligand EGF have been studied as biomarkers for anti-EGFR treatment. However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin...
Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency [0.03%]
用于筛查二氢嘧啶脱氢酶缺乏症预测试验的评估
M C van Staveren,H Jan Guchelaar,A B P van Kuilenburg et al.
M C van Staveren et al.
5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enz...